Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Locally Advanced Prostate Cancer × Docetaxel × Genitourinary × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 257 Urinary Bladder Neoplasms 35 Neoplasm Metastasis 27 Carcinoma, Non-Small-Cell Lung 21 Carcinoma, Transitional Cell 20 Neoplasms 19 Breast Neoplasms 18 Lung Neoplasms 13 Carcinoma, Renal Cell 12 Stomach Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 10 Ovarian Neoplasms 10 Non-Muscle Invasive Bladder Neoplasms 10 Melanoma 8 Urethral Neoplasms 6 Head and Neck Neoplasms 6 Esthesioneuroblastoma, Olfactory 6 Esophageal Neoplasms 6 Triple Negative Breast Neoplasms 5 Small Cell Lung Carcinoma 5 Salivary Gland Neoplasms 5 Prostatic Neoplasms, Castration-Resistant 5 Prostate Cancer Metastatic 5 Metastatic Castration-resistant Prostate Cancer 5 Kidney Neoplasms 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 4 Pancreatic Neoplasms 4 Pain 4

Interventions

tislelizumab 1 pamiparib 1 TNFeraseBiologic 1 Injections 1 Gefitinib 1 Docetaxel 1 Cisplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06387056 2024-04-26

SEGNO

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting

Locally Advanced Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡